SPOTLIGHT -
Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.
Read More
Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas
Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.
Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
